CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
25.95
-0.12 (-0.46%)
Jun 27, 2025, 4:00 PM - Market closed
CG Oncology Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for CG Oncology stock ranges from a low of $41 to a high of $75. The average analyst price target of $64.44 forecasts a 148.32% increase in the stock price over the next year.
Price Target: $64.44 (+148.32%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $52 → $56 | Buy | Maintains | $52 → $56 | +115.80% | Jun 17, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $55 → $52 | Buy | Maintains | $55 → $52 | +100.39% | May 19, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $41 | Buy | Initiates | $41 | +58.00% | May 2, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $66 → $68 | Buy | Maintains | $66 → $68 | +162.04% | Apr 29, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $75 | Buy | Reiterates | $75 | +189.02% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
452.25K
from 1.14M
Decreased by -60.29%
Revenue Next Year
114.45M
from 452.25K
Increased by 25,206.93%
EPS This Year
-1.90
from -1.41
EPS Next Year
-1.74
from -1.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.0M | 268.6M | 347.8M | ||
| Avg | 452,248 | 114.5M | 214.4M | ||
| Low | n/a | 19.6M | 122.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 75.2% | 59,281.2% | 203.9% | ||
| Avg | -60.3% | 25,206.9% | 87.3% | ||
| Low | - | 4,233.9% | 7.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.65 | -0.32 | 0.62 | ||
| Avg | -1.90 | -1.74 | -0.43 | ||
| Low | -2.16 | -3.51 | -2.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.